相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
HT Mouridsen et al.
CANCER RESEARCH (2010)
Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8.
R Jakesz et al.
CANCER RESEARCH (2010)
Circulating tumor cells in breast cancer: Fiction or reality?
Massimo Cristofanilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer
J. Michael Dixon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast Cancer
Yu Shen et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Intratumoral estrogen production in breast carcinoma: significance of aromatase
Takashi Suzuki et al.
BREAST CANCER (2008)
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
Paul E. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
L. Perey et al.
ANNALS OF ONCOLOGY (2007)
Duration of letrozole treatment and outcomes in the placebo-controlled NCICCTG MA.17 extended adjuvant therapy trial
James N. Ingle et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Concordance among gene-expression-based predictors for breast cancer
Cheng Fan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01)
M Belfiglio et al.
CANCER (2005)
Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17
PE Goss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
R Jakesz et al.
LANCET (2005)
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis et al.
CLINICAL CANCER RESEARCH (2005)
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
SA Nowell et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
R Iaffaioli et al.
BRITISH JOURNAL OF CANCER (2005)
American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004
EP Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer
G Bertelli et al.
ONCOLOGY (2005)
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
P Wegman et al.
BREAST CANCER RESEARCH (2005)
Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
RC Coombes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - Results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses
CANCER (2003)
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
R Paridaens et al.
ANNALS OF ONCOLOGY (2003)
Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:: survival analysis and updated safety results
JM Nabholtz et al.
EUROPEAN JOURNAL OF CANCER (2003)
Drug therapy: Aromatase inhibitors in breast cancer
IE Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effects of tamoxifen on benign breast disease in women at high risk for breast cancer
E Tan-Chiu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Overview of the main outcomes in breast-cancer prevention trials
J Cuzick et al.
LANCET (2003)
Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women
U Veronesi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
A mechanism of drug resistance to tamoxifen in breast cancer
JM Schafer et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2002)
Double-blind, Randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial
CK Osborne et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002
EP Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years
HJ Stewart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial
JA Cauley et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
分享论文
